Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 2/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | KDM1A | O60341 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.49 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.49 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | IKBKB | O14920 | 1/20 | 0.47 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.47 |
| ▸ | HTR3B | O95264 | 1/20 | 0.47 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.47 |
| ▸ | HTR3A | P46098 | 1/20 | 0.47 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.47 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7480710 | 0.98 | HRH1 (0.63) | HRH1TDP1KDM1AMAOAMAOB | |
| SCHEMBL31142632 | 0.89 | CHRNB2 (0.53) | HRH1TDP1MAOAHTR2CROCK1 | |
| Hydrochloric Acid SCHEMBL31142619 | 0.87 | CHRNB2 (0.51) | HRH1TDP1MAOAHTR2CROCK1 | |
| SCHEMBL16838744 | 0.85 | SMN1; SMN2 (0.56) | HRH1TDP1KDM1AMAOAMAOB | |
| SCHEMBL12167875 | 0.84 | HRH1 (0.55) | HRH1TDP1MAOAMAOBACVR1B | |
| SCHEMBL2365784 | 0.84 | HRH1 (0.66) | HRH1ACVR1BTGFBR1ACVR1KCNH2 | |
| SCHEMBL2019376 | 0.83 | HRH1 (0.70) | HRH1ACVR1BTGFBR1ACVR1KCNH2 | |
| Hydrochloric Acid SCHEMBL31587801 | 0.82 | HRH1 (0.63) | HRH1TDP1ACVR1BTGFBR1ACVR1 | |
| SCHEMBL942733 | 0.82 | HRH1 (0.62) | HRH1IKBKBADRB1HTR2C | |
| SCHEMBL29995290 | 0.82 | HRH1 (0.62) | HRH1IKBKBADRB1HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019203427-A1 | CHELATING AGENT HAVING EXCELLENT PROPERTY OF SELECTIVELY FORMING COMPLEX WITH SPECIFIC METAL ION, AND PRODUCTION METHOD THEREFOR | (주)이엠티 | 2019-10-24 | — | — | WO | claimed |
| US-20170342049-A1 | NOVEL 1,3,5 -TRIAZINE BASED PI3K INHIBITORS AS ANTICANCER AGENTS AND A PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2017-11-30 | — | — | US | claimed |
| EP-3221307-A1 | NOVEL 1,3,5 -TRIAZINE BASED PI3K INHIBITORS AS ANTICANCER AGENTS AND A PROCESS FOR THE PREPARATION THEREOF | Council of Scientific and Industrial Research (IN) | 2017-09-27 | — | — | EP | claimed |
| WO-2016079760-A1 | NOVEL 1,3,5 -TRIAZINE BASED PI3K INHIBITORS AS ANTICANCER AGENTS AND A PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2016-05-26 | — | — | WO | claimed |
| US-8592595-B2 | Preparation of (N-heterocyclyl) aryl ethers | SALTIGO GMBH (DE) | 2013-11-26 | — | — | US | claimed |
| US-20100152454-A1 | PREPARATION OF (N-HETEROCYCLYL) ARYL ETHERS | SALTIGO GMBH (DE) | 2010-06-17 | — | — | US | claimed |
| EP-2179988-A1 | Producing (N-heterocyclic) aryl ethers | Saltigo GmbH (DE) | 2010-04-28 | — | — | EP | claimed |
| US-20240285614-A1 | PHENOL RIBONUCLEOTIDE REDUCTASE (RNR) INHIBITORS AND USES THEREOF | BOUNDLESS BIO, INC. | 2024-08-29 | — | — | US | disclosed |
| US-20230062100-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-03-02 | — | — | US | disclosed |
| US-20230062100-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-03-02 | — | — | US | disclosed |
| EP-4065570-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | Bayer Aktiengesellschaft (DE) | 2022-10-05 | — | — | EP | disclosed |
| WO-2021105115-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2021-06-03 | — | — | WO | disclosed |
| WO-2021105115-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2021-06-03 | — | — | WO | disclosed |
| EP-1370536-A1 | METALLOPROTEINASE INHIBITORS | AstraZeneca AB (SE) | 2003-12-17 | — | — | EP | disclosed |
| US-6525070-B2 | For therapy of chemokine (such as CCR3) or H1 mediated disease state | ASTRAZENECA AB (SE) | 2003-02-25 | — | — | US | disclosed |
| WO-2002074767-A1 | METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | WO | disclosed |
| WO-2002074750-A1 | METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | WO | disclosed |
| EP-0635505-B1 | 4-Aryloxy- and 4-arylthiopiperidine derivatives | MERCK PATENT GMBH (DE) | 1997-10-15 | — | — | EP | disclosed |
| US-5561145-A | 4-aryloxy- and 4-arylthiopiperidine derivatives | MERCK PATENT GESELLSCHAFT MIT BESHRANKTER HAFTUNG (DE) | 1996-10-01 | — | — | US | disclosed |
| EP-0635505-A1 | 4-Aryloxy- and 4-arylthiopiperidine derivatives | MERCK PATENT GmbH (DE) | 1995-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240285614-A1 | PHENOL RIBONUCLEOTIDE REDUCTASE (RNR) INHIBITORS AND USES THEREOF | RRM2B, RRM2, RRM1 | HRH1 3983/4885TDP1 520/4885KDM1A 2078/4885 |
| US-20230062100-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | DGKK, DGKG, DGKA | HRH1 326/4885TDP1 1402/4885KDM1A 1468/4885 |
| US-20170342049-A1 | NOVEL 1,3,5 -TRIAZINE BASED PI3K INHIBITORS AS ANTICANCER AGENTS AND A PROCESS FOR THE PREPARATION THEREOF | PIK3CA, PIK3R5, PIK3CD | HRH1 3298/4885TDP1 1480/4885KDM1A 1469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.